Alpha Teknova (NASDAQ:TKNO – Get Free Report) was upgraded by equities research analysts at Roth Capital to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Teknova in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Alpha Teknova presently has a consensus rating of “Hold” and a consensus target price of $7.00.
Read Our Latest Analysis on TKNO
Alpha Teknova Price Performance
Alpha Teknova (NASDAQ:TKNO – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $12.19 million for the quarter, compared to analyst estimates of $10.95 million. Alpha Teknova had a negative return on equity of 24.32% and a negative net margin of 41.07%.
Hedge Funds Weigh In On Alpha Teknova
Large investors have recently added to or reduced their stakes in the business. Walleye Capital LLC purchased a new position in Alpha Teknova during the second quarter worth approximately $263,000. Roubaix Capital LLC boosted its position in Alpha Teknova by 88.5% in the 1st quarter. Roubaix Capital LLC now owns 1,882,355 shares of the company’s stock valued at $5,440,000 after buying an additional 883,823 shares during the last quarter. R Squared Ltd acquired a new position in shares of Alpha Teknova in the first quarter worth about $42,000. XTX Topco Ltd purchased a new position in Alpha Teknova in the fourth quarter valued at about $77,000. Finally, Marshall Wace LLP grew its stake in Alpha Teknova by 286.1% during the 4th quarter. Marshall Wace LLP now owns 50,156 shares of the company’s stock valued at $191,000 after purchasing an additional 37,164 shares in the last quarter. 13.81% of the stock is currently owned by hedge funds and other institutional investors.
About Alpha Teknova
Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.
The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.
Featured Articles
- Five stocks we like better than Alpha Teknova
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
